AgeX Therapeutics (AgeX Therapeutics) Momentum Rank : 0 (As of May. 06, 2024)

View and export this data going back to 2018. Start your Free Trial

What is AgeX Therapeutics Momentum Rank?

AgeX Therapeutics has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

AgeX Therapeutics Momentum Rank Related Terms

Thank you for viewing the detailed overview of AgeX Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

AgeX Therapeutics (AgeX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AgeX Therapeutics Inc (AMEX:AGE) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

0X4:Germany 0X4:Germany

Address

1101 Marina Village Parkway, Suite 201, Alameda, CA, USA, 94501

Website

https://www.agexinc.com

AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.

Executives

Jean-christophe Renondin	director	505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022
Juvenescence Us Corp.	director, 10 percent owner	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Joanne M. Hackett	director	C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708
Park Andrea Eun Jae	officer: Chief Financial Officer	C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501
Michael H May	director	965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501
Michael D West	director, officer: Chief Executive Officer	AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501
Michael H. Mulroy	director	1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Russell Skibsted	officer: Chief Financial Officer	15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Judith Segall	officer: Corporate Secretary	1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Hal Sternberg	officer: Vice President-Research	935 PARDEE STREET, BERKELEY CA 94710
Annalisa Jenkins	director	C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
John F Mauldin	director	3204 BEVERLY DRIVE, DALLAS TX 75205
Gregory Bailey	director	4 A CHESHAM STREET, LONDON X0 SW1X8DT
Juvenescence Ltd	10 percent owner	1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB
Nafees Naseer Malik	officer: Chief Operating Officer	C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501